46 results found.

Ulcerative Colitis Clinical Trial using Methotrexate

University of North Carolina, Chapel Hill - Recruiting 18 years to 70 years.
- Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC).
Methotrexate

Ulcerative Colitis Clinical Trial using AMG 181; Placebo

Amgen - Recruiting 18 years to 65 years.
- A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis.
AMG 181; Placebo

Crohn Disease, or Ulcerative Colitis Clinical Trial using VSL#3

Charles University, Czech Republic - Recruiting N/A or older.
- The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease.
VSL#3

Ulcerative Colitis Clinical Trial using rhuMAb Beta7

Genentech - Recruiting 18 years to 75 years.
- A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Rhumab Beta7 in Patients With Moderate to Severe Ulcerative Colitis.
rhuMAb Beta7

Hepatosplenic T-Cell Lymphoma Clinical Trial using Collection of samples

Janssen Scientific Affairs, LLC - Recruiting N/A or older.
- A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL).
Collection of samples

Ulcerative Colitis Clinical Trial

AbbVie - Recruiting N/A or older.
- Special Investigation in Patients With Ulcerative Colitis.

Colitis, Ulcerative Clinical Trial using Golimumab

Janssen Research & Development, LLC - Recruiting 2 years to 17 years.
- A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFà Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis.
Golimumab

Inflammatory Bowel Disease, Crohn's Disease, or Ulcerative Coliti Clinical Trial using Infliximab, adalimumab, certolizumab pegol

Oslo University Hospital - Recruiting 18 years or older.
- Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease.
Infliximab, adalimumab, certolizumab pegol

Colitis, Ulcerative Clinical Trial using Golimumab; Placebo

Janssen Pharmaceutical K.K. - Recruiting 18 years to 70 years.
- A Phase 3 Multicenter, Placebo-controlled, Double-blind, Randomized-withdrawal Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.
Golimumab; Placebo

Ulcerative Colitis Clinical Trial using SAR339658; Placebo

Sanofi - Recruiting 18 years to 70 years.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC).
SAR339658; Placebo

Ulcerative Colitis Clinical Trial using SAR339658

Sanofi - Recruiting 18 years or older.
- A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC).
SAR339658

Colitis, Ulcerative Clinical Trial using Placebo; JNJ-54781532 25 mg once daily; JNJ-54781532 75 mg once daily; JNJ-54781532 150 mg once daily; JNJ-54781532 75 mg twice daily

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis.
Placebo; JNJ-54781532 25 mg once daily; JNJ-54781532 75 mg once daily; JNJ-54781532 150 mg once daily; JNJ-54781532 75 mg twice daily

Ulcerative Colitis Clinical Trial using MEDI7183 low dose; MEDI7183 medium dose; MEDI7183 high dose; Matching Placebo

AstraZeneca - Recruiting 18 years to 65 years.
- .
MEDI7183 low dose; MEDI7183 medium dose; MEDI7183 high dose; Matching Placebo

Colitis, Ulcerative Clinical Trial using Trichuris suis ova (TSO); Placebo

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 70 years.
- A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis and Its Effects on Mucosal Immune State and Microbiota.
Trichuris suis ova (TSO); Placebo

Colitis, Ulcerative Clinical Trial using Yoga; Self-care

Universit„t Duisburg-Essen - Recruiting 18 years to 70 years.
- Randomized-controlled Trial of Yoga for Ulcerative Colitis.
Yoga; Self-care

Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Diseas Clinical Trial using lumbar puncture

Pfizer - Recruiting 18 years to 75 years.
- A Multi Center, Phase 1, Open Label Evaluation Of The Effect Of PF-00547659 (Anti Madcam Monoclonal Antibody) On Cerebrospinal Fluid (CSF) Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Are Anti- TNF Inadequate Responders (TOSCA).
lumbar puncture

Ulcerative Colitis Clinical Trial using PF-00547659

Pfizer - Recruiting 18 years to 76 years.
- A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Ulcerative Colitis (TURANDOT II).
PF-00547659

Ulcerative Colitis Clinical Trial using tofacitinib; Placebo

Pfizer - Recruiting 18 years or older.
- Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
tofacitinib; Placebo

Ulcerative Colitis Clinical Trial using Fecal Microbiota Transplant

Baylor College of Medicine - Recruiting 12 years to 20 years.
- A Phase I Study of Fecal Microbiota Transplantation (FMT) in Immunomodulator Dependent Pediatric Ulcerative Colitis (UC).
Fecal Microbiota Transplant

Crohn's Disease, Inflammatory Bowel Disease, or Ulcerative Coliti Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 75 years.
- Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut.

Ulcerative Colitis Clinical Trial using polyethylene glycol; Ascorbic Acid

Keimyung University Dongsan Medical Center - Recruiting 18 years to 80 years.
- Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Patients With Inactive Ulcerative Colitis; Randomized, Single Blind, Multicenter Study.
polyethylene glycol; Ascorbic Acid

Colitis, Ulcerative Clinical Trial using Golimumab

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis.
Golimumab

Colitis, Ulcerative Clinical Trial using GSK2586184

GlaxoSmithKline - Recruiting 18 years to 75 years.
- An Open Label, Experimental Medicine Investigation of the Safety and Tolerability of 400 mg b.i.d. GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis..
GSK2586184

Acute Severe Ulcerative Colitis, Acute Severe Colitis, or Crohn's Clinical Trial using AB (antibiotics); CS (corticosteroids) Only

Shaare Zedek Medical Center - Recruiting 2 years to 75 years.
- Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial.
AB (antibiotics); CS (corticosteroids) Only

Ulcerative Colitis Clinical Trial using tofacitinib; Placebo

Pfizer - Recruiting 18 years or older.
- A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
tofacitinib; Placebo

Ulcerative Colitis Clinical Trial using Placebo; CP690,550

Pfizer - Recruiting 18 years or older.
- A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis.
Placebo; CP690,550

Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, or In Clinical Trial using Anti TNF therapy including infliximab; No Biologics

Janssen Biotech, Inc. - Recruiting 1 Month to 17 years.
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease.
Anti TNF therapy including infliximab; No Biologics

Ulcerative Colitis Clinical Trial using GWP42003; Placebo

GW Pharmaceuticals Ltd. - Recruiting 18 years or older.
- A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis..
GWP42003; Placebo

Ulcerative Colitis Clinical Trial using Adalimumab; Immunomodulatory therapy

AbbVie - Recruiting 18 years or older.
- A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRAr (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC).
Adalimumab; Immunomodulatory therapy

Ulcerative Colitis Clinical Trial using Motilis-3D transit

University of Aarhus - Recruiting 18 years to 85 years.
- Gastrointestinal Transit Times and Motility in Patients Suffering From Severe Ulcerative Colitis Obtained by Motilis-3D-transit.
Motilis-3D transit

Ulcerative Colitis Clinical Trial using Motilis-3D-transit

University of Aarhus - Recruiting 18 years to 85 years.
- Gastrointestinal Motility in Patients Suffering From Severe Ulcerative Colitis Obtained by Motilis-3D-transit.
Motilis-3D-transit

Ulcerative Colitis Clinical Trial using Trichuris suis ova

New York University School of Medicine - Recruiting 18 years to 72 years.
- Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova.
Trichuris suis ova

Ulcerative Colitis Clinical Trial using GLPG0974; Placebo

Galapagos NV - Recruiting 18 years to 75 years.
- Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis.
GLPG0974; Placebo

Ulcerative Colitis Clinical Trial using carrageenan; dietary intervention with no-carrageenan diet

University of Illinois at Chicago - Recruiting 18 years or older.
- Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity.
carrageenan; dietary intervention with no-carrageenan diet

Ulcerative Colitis Clinical Trial using HMPL-004 tablet; Placebo

Hutchison Medipharma Limited - Recruiting 18 years to 75 years.
- A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis.
HMPL-004 tablet; Placebo

Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, or In Clinical Trial using Blood and stool sample

Boston Medical Center - Recruiting 18 years or older.
- Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients.
Blood and stool sample

Ulcerative Colitis Clinical Trial using Rectal tacrolimus; Placebo

The University of Western Australia - Recruiting 18 years or older.
- A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis.
Rectal tacrolimus; Placebo

Ulcerative Colitis Clinical Trial using Photodynamic therapy with Gliolan

University of Zurich - Recruiting 18 years or older.
- A Multicenter, Open Phase II Study to Assess the Effect and Safety of 'Low Dose' Photodynamic Therapy in Patients With Moderate to Severe Active Distal Ulcerative Colitis.
Photodynamic therapy with Gliolan

Colitis, Ulcerative Clinical Trial using Placebo; Anti-IP-10 Antibody

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC).
Placebo; Anti-IP-10 Antibody

Crohn's Disease, Ulcerative Colitis, or Inflammatory Bowel Diseas Clinical Trial

Medical College of Wisconsin - Recruiting N/A to 18 years.
- Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease.

Ulcerative Colitis Clinical Trial using Granulocyte Monocyte Apheresis (GMA-Apheresis)

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - Recruiting 18 years to 75 years.
- An Open Randomized Multicenter Clinical Investigation to Compare the Efficacy and Safety of Prednisone Plus Adacolumnr GMA Apheresis vs Prednisone Alone in the Treatment of Patients With Mild or Moderately Active Steroid Dependent Ulcerative Colitis.
Granulocyte Monocyte Apheresis (GMA-Apheresis)

Crohn's Disease, or Ulcerative Colitis Clinical Trial using smoking of cannabis; smoking cigarettes with placebo

Meir Medical Center - Recruiting 20 years to 70 years.
- A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease.
smoking of cannabis; smoking cigarettes with placebo

Ulcerative Colitis Clinical Trial using conventional white light colonoscopy; FICE (Fujinon Intelligent Chromoendoscopy)

Centre Hospitalier Universitaire de Nice - Recruiting 18 years or older.
- Comparaison de la Chromo Endoscopie Virtuelle FICE (Fujinon Intelligent Chromoendoscopy) Avec la Coloscopie Conventionnelle Dans la d‚tection de la Dysplasie Chez Patients Porteurs de Recto Colite ulc‚ro h‚morragique (RCH)..
conventional white light colonoscopy; FICE (Fujinon Intelligent Chromoendoscopy)

Ulcerative Colitis Clinical Trial using Coltect

Tel-Aviv Sourasky Medical Center - Recruiting 18 years to 75 years.
- The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label.
Coltect

Ulcerative Colitis Clinical Trial using Narrow Band Imaging; colonoscopy

North West London Hospitals NHS Trust - Recruiting 18 years or older.
- Randomised,Controlled Trial of Narrow Band Imaging With Magnification (NBI) Versus White Light Endoscopy for Dysplasia Detection in Ulcerative Colitis Surveillance.
Narrow Band Imaging; colonoscopy

Inflammatory Bowel Disease, Ulcerative Colitis, or Crohn's Diseas Clinical Trial

Children's Hospital Boston - Recruiting N/A to 18 years.
- Phase I Evaluation of Urinary Isoprostane Levels in Pediatric Patients With Inflammatory and Non-Inflammatory Gastrointestinal Disease.